Arialys Therapeutics announces U.S. FDA fast track designation for ART5803, the first precision therapeutic candidate in development for the treatment of anti-nmda receptor encephalitis Business Wire (Press Release) 2d
Proteina shares surge 19% after AI antibody option deal with Samsung Bioepis Korea Biomedical Review 2d
FB102 Achieves statistically significant improvement in vitiligo at week 24 after completion of 12-week treatment period Business Wire (Press Release) 2d
INTENT Biologics receives FDA Breakthrough Therapy Designation for PEP Biologic for its Phase 3 ready flagship indication Drugs Discovery Online 2d
AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial The Times of India 2d